HLA-G Is Differentially Expressed in Thyroid Tissues

Feitosa, Nathalie Lobo de Figueiredo; Crispim, Janaina Cristina de Oliveira; Zanetti, Bruna Riedo; Magalhães, Patrícia Künzle Ribeiro; Soares, Christiane Pienna; Soares, Edson García; Neder, Luciano; Donadi, Eduardo Antônio; Maciel, Léa Maria Zanini

doi:10.1089/thy.2013.0246

Cited by 26 publications

(38 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, thyroid cancer is found in 5%-10% of the cases, and it is the most common malignant neoplasia of the endocrine system. PTC and FTC are classified as differentiated tumors, represent 90% of the cases, and are derived from follicular cells (3). Early diagnosis and treatment of thyroid cancer is crucial for improved prognosis and a better survival rate.…”

Section: Discussionmentioning

confidence: 99%

Plasma human leukocyte antigen-G (HLA-G) in patients with thyroid cancer

Akın¹,

Aral²,

Yavuz³

et al. 2017

Turk J Med Sci

View full text Add to dashboard Cite

Background/aim: A number of tumor markers detected in the serum or pathological specimens using immunohistochemical methods are used for early detection of malignancies and postoperative follow-up. Human leukocyte antigen-G (HLA-G) is a nonclassic HLA class I molecule. Recent studies suggested a relationship between HLA-G positivity and the stage or the phenotype of the malignancy. In this study, the relationship between serum HLA-G positivity and thyroid cancer was investigated.Materials and methods: Fifty patients with thyroid cancer and 45 healthy volunteers were included in this study. Serum HLA-G levels were measured using ELISA.Results: HLA-G was positive in only 3 out of 50 patients with thyroid cancer (2 papillary, 1 follicular type). On the other hand, HLA-G was positive in 20 out of 45 healthy subjects (P < 0.001). The prevalence of detectable levels of serum HLA-G was independent of sex and age in the whole study population. No correlation was found between serum HLA-G value and thyroid hormone profile, neither in papillary thyroid cancer nor follicular thyroid cancer patients. Conclusion:In this study, serum HLA-G was significantly less common in patients with thyroid cancer than in healthy controls.

show abstract

Section: Discussionmentioning

confidence: 99%

Plasma human leukocyte antigen-G (HLA-G) in patients with thyroid cancer

Akın¹,

Aral²,

Yavuz³

et al. 2017

Turk J Med Sci

View full text Add to dashboard Cite

show abstract

“…We studied 135 patients with malignant and benign thyroid diseases who underwent thyroidectomy from 2000 to 2011 and were followed up at the Thyroid Outpatient Clinic of the Division of Endocrinology of FMRP‐USP. We selected these patients from our previous study of HLA‐G expression in thyroid tissues . DNA was extracted from peripheral blood mononuclear cells obtained from 72 papillary thyroid carcinomas (PTC), 22 follicular thyroid carcinomas (FTC), 19 follicular adenomas (FA) and 21 colloid goitres.…”

Section: Methodsmentioning

confidence: 99%

“…Goitre hyperplastic areas exhibit weak expression, benign lesions present mild expression, and in malignant thyroid neoplasia HLA‐G is strongly expressed. In addition, risk factors associated with worse prognosis, including tumour size and the presence of papillary classic histological subtype in thyroid carcinoma (PTC), were associated with increased HLA‐G expression . Other authors have also observed increased HLA‐G expression in specimens of patients exhibiting PTC and increased plasma soluble HLA‐G (sHLA‐G) levels in patients .…”

Section: Introductionmentioning

confidence: 99%

HLA‐G 3′ untranslated region polymorphic sites associated with increased HLA‐G production are more frequent in patients exhibiting differentiated thyroid tumours

Figueiredo-Feitosa

Palomino

Alves

et al. 2017

Clinical Endocrinology

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, more studies on the complete HLA-G gene and its linkage disequilibrium with other genes and on HLA-G expression at both the tumor site and plasma in a specific microenvironment are required to consolidate these findings. carcinoma (69,70), esophageal squamous cell carcinoma (71)(72)(73)(74), gastric cancer (75)(76)(77), glioblastoma (78), hepatocellular carcinoma (79)(80)(81), lung cancer (82)(83)(84), nasopharyngeal carcinoma (85), oral cavity squamous cell carcinoma (86), ovarian cancer (87-89), pancreatic adenocarcinoma (90), thyroid carcinoma (91,92). These data were summarized in Table 1.…”

Section: Relevance Of Hla-g Expression In Cancersmentioning

confidence: 99%

Human Leukocyte Antigen-G (HLA-G) Expression in Cancers: Roles in Immune Evasion, Metastasis and Target for Therapy

Lin

Yan

2015

Mol Med

109

View full text Add to dashboard Cite

Aberrant induction of human leukocyte antigen-G (HLA-G) expression has been observed in various malignancies and is strongly associated with tumor immune escape, metastasis and poor prognosis. To date, great achievements have been made in understanding the underlying mechanisms of HLA-G involved in tumor progression. HLA-G could lead to tumor evasion by inhibition of immune cell cytolysis, differentiation and proliferation and inhibition of cytokine production, induction of immune cell apoptosis, generation of regulatory cells and expansion of myeloid-derived suppressive cells and by impairment of chemotaxis. Moreover, HLA-G could arm tumor cells with a higher invasive and metastatic potential with the upregulation of tumor-promoting factor expression such as matrix metalloproteinases (MMPs), indicating that ectopic HLA-G expression could render multiple effects during the progression of malignancies. In this review, we summarized the mechanisms of HLA-G involved in promoting tumor cell immune escaping, metastasis and disease progression. Special attention will be paid to its significance as an attractive therapeutic target in cancers.

show abstract

HLA-G Is Differentially Expressed in Thyroid Tissues

Cited by 26 publications

References 38 publications

Plasma human leukocyte antigen-G (HLA-G) in patients with thyroid cancer

Plasma human leukocyte antigen-G (HLA-G) in patients with thyroid cancer

HLA‐G 3′ untranslated region polymorphic sites associated with increased HLA‐G production are more frequent in patients exhibiting differentiated thyroid tumours

Human Leukocyte Antigen-G (HLA-G) Expression in Cancers: Roles in Immune Evasion, Metastasis and Target for Therapy

Contact Info

Product

Resources

About